# Fate Therapeutics

Source: https://onco.cc/companies/fate-therapeutics/  
OnCo record `fate-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.

## Summary

Fate Therapeutics, based in San Diego and listed as FATE, builds off-the-shelf CAR-T and CAR-NK cells derived from induced pluripotent stem cells, including FT819 and FT522, for cancer and autoimmune disease. FT819 is a clonal iPSC-derived CD19 CAR-T, FT522 is a CD19 CAR-NK with alloimmune defence receptors designed to avoid conditioning chemotherapy, the company presented at ASCO and EULAR 2026, and it has a solid-tumour collaboration with Ono. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy, CAR-NK and CAR-T, to CD19 as a target and to ideas on qualifying one iPSC master cell bank for many products. Manufacturing cost and time for living medicines is the bottleneck iPSC-derived cells are meant to relieve. Whether iPSC-derived cells persist and perform as well as patient-derived ones is the open question.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: San Diego, CA
- Type: cell-therapy
- Website: https://fatetherapeutics.com
- Ticker: FATE

## Sources

- ASCO/EULAR 2026: https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-presentations-2026-asco-and-eular

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Allogeneic cell banks: one donor, hundreds of doses](https://onco.cc/technologies/allogeneic-cell-banks/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- ideas: [Off-the-shelf natural killer cells to sweep up residual disease](https://onco.cc/ideas/idea-bio2-nk-cells-for-mrd/), [Qualify one iPSC master cell bank once for many off-the-shelf cell products](https://onco.cc/ideas/idea-reg-ipsc-master-bank-qualified-once/)
- institutions: [Masonic Cancer Center, University of Minnesota](https://onco.cc/institutions/minnesota-masonic/)

---
JSON: https://onco.cc/api/v1/entities/fate-therapeutics.json